These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt 2016-003998-17 A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE) 2024-04-24 not-yet-due
Completed, report not yet due 2016-004526-41 A PHASE Ib/II STUDY TO EVALUATE SAFETY AND EFFICACY OF ATEZOLIZUMAB COMBINED WITH RADIO-CHEMOTHERAPY IN A PREOPERATIVE SETTING FOR PATIENTS WITH LOCALIZED RECTAL CANCER (R-IMMUNE) 2024-10-15 not-yet-due
Completed, report not yet due 2020-000473-25 ESKETamine for FIBromyalgia treatment Perfusions intraveineuses de S-KETAMINE dans les syndromes fibromyalgiques : une étude exploratoire 2024-10-22 not-yet-due